HB 429 Delaware House · 153rd General Assembly (2025-2026)

AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO THE STEP THERAPY EXCEPTION PROCESS.

Summary
This Act modernizes Delaware law by adding modern medical treatment options biologics or biosimilars to the step therapy exception process. The current law was passed before biosimilars were widely available. Biosimilars are to biologics what generic drugs are to traditional drugs once their exclusivity expires. This revision adds an exclusion to step therapy protocol exceptions for interchangeable biologics and biosimilars.
Bill status signed all 5 stages cleared
Introduction
May 2026
Committee Review
Jun 2026
House Passage
Jun 2026
Senate Passage
Jun 2026
Signed into Law
Jul 2026
Introduced May 19, 2026 Signed Jul 23, 2026
Floor votes · Senate Jun 24, 2026 · House Jun 11, 2026

How they voted

210
Passed
Total votes 21
Jun 24, 2026
D Democratic15
15 Yea
100% Yea
R Republican6
6 Yea
100% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
7
Key actions
5
Committee
2
Jul 23, 2026
Signed into law
Signed by Governor
executive
Jun 24, 2026
Upper · Passed
Passed By Senate. Votes: 21 YES
upper
Jun 23, 2026
Upper · Passed
Reported Out of Committee (Banking, Business, Insurance & Technology) in Senate with 5 On Its Merits
upper
Jun 11, 2026
Introduced
Assigned to Banking, Business, Insurance & Technology Committee in Senate
upper
Jun 11, 2026
Lower · Passed
Passed By House. Votes: 38 YES 1 NO 2 ABSENT
lower
Jun 9, 2026
Lower · Passed
Reported Out of Committee (Economic Development/Banking/Insurance & Commerce) in House with 3 Favorable, 6 On Its Merits
lower
May 19, 2026
Introduced
Introduced and Assigned to Economic Development/Banking/Insurance & Commerce Committee in House
lower
13 primary · 0 co-sponsors

Sponsors